Ensigna Biosystems is a contract research organization specializing in advanced histopathology and genomic services tailored for the pharmaceutical and biotechnology sectors. The company leverages its founders' extensive expertise in molecular pathology, pharmacology, drug discovery, and genomics to provide comprehensive solutions that support drug discovery and translational biomedical research. Their service offerings encompass a wide range of techniques, including histopathology, immunohistochemistry (IHC), antibody validation, image analysis, and gene expression analysis. This integrated approach ensures that clients receive not only high-quality data but also strategic consultation throughout the research process.

One of the standout technologies offered by Ensigna is the NanoString GeoMx Digital Spatial Profiling (DSP), which enables high-plex and high-throughput spatial profiling of RNA and protein from a single formalin-fixed, paraffin-embedded (FFPE) section. This innovative platform allows researchers to conduct detailed biomarker imaging with spatial quantification, enhancing the understanding of tissue architecture and protein expression. Additionally, Ensigna provides robust image analysis capabilities, transforming IHC slides into quantitative data while preserving the histological structure of tissues, thereby facilitating accurate measurements of protein expression across different tissue regions.

United States

Ensigna Biosystems is a contract research organization that provides cutting-edge molecular pathology and genomic services to the biopharmaceutical industry. By combining traditional pathology services with genomics, Ensigna Biosystems is able to characterize biological samples based on protein expression, mRNA levels and mutational status, thus enabling the development of targeted therapies and the implementation of personalized medicine.

Ensigna Biosystems

Company Details